Tricuspid Valve Repair System Shows Promising Results at One-year Follow-up
Study further validates transcatheter edge-to-edge strategy to treat tricuspid regurgitation.
Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study further validates transcatheter edge-to-edge strategy to treat tricuspid regurgitation.
Medtronic plc today announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which were presented today at the American College
Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who received a novel investigational device intended to repair the defective valve experienced significant improvements in blood flow through the heart and in quality of life at one year, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.
/PRNewswire/ -- Meddux, an engineering, design, development and manufacturing company serving OEMs, CEOs, Physicians, Universities, and Start-ups for the...
/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data from the first 80 patients in the SPYRAL...